Turner Syndrome and the Heart
- 1 January 2002
- journal article
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 2 (6) , 401-413
Abstract
Turner syndrome is a condition usually associated with reduced final height, gonadal dysgenesis, and thus insufficient circulating levels of female sex steroids, and infertility. A number of other signs and symptoms are seen more frequently with the syndrome. With respect to cardiac function, congenital malformations of the heart and the great vessels, hypertension and ischemic heart disease, and increased risk of aortic dissection are all conditions that the pediatrician or the physician caring for females with Turner syndrome should keep in mind. Many girls and adolescents with Turner syndrome receive growth hormone (GH) treatment, which has so far been an effective and well-tolerated therapy. Nevertheless, because of the experience from acromegaly, the physician should monitor blood pressure and perform echocardiography, together with clinical examinations by a cardiologist at regular intervals. During adulthood most women with Turner syndrome are faced with premature menopause and the need for female hormone replacement therapy (HRT). During clinical evaluation of girls and women with Turner syndrome, these conditions and complications should be kept under surveillance. Here the cardiovascular complications of Turner syndrome are reviewed. The risk of congenital heart defects such as bicuspid aortic valves, aortic coarctation, other valve abnormalities, and septal defect is increased. Likewise, the risk of aortic dissection at a young age is increased, as is the risk of hypertension, ischemic heart disease, and stroke. GH therapy does not seem to adversely affect the heart, although longer-term follow-up studies are needed. In short-term studies, HRT lowers blood pressure, while any effect on the risk of ischemic heart disease has not been evaluated. Treatment with GH and HRT are discussed in relation to the heart and great vessels. Presently, the pathophysiology of the congenital cardiovascular malformation in Turner syndrome is unexplained, although different theories exist. Recommendations for clinical practice are given, including life-long surveillance of cardiac function, aortic diameter and blood pressure.Keywords
This publication has 107 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner’s syndromeThe Journal of Pediatrics, 1999
- Congenital heart disease in patients with Turner’s syndromeThe Journal of Pediatrics, 1998
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Chromosome abnormalities found among 34910 newborn children: results from a 13-year incidence study in rhus, DenmarkHuman Genetics, 1991
- High incidence of thyroid disturbances in 49 children with Turner syndromeThe Journal of Pediatrics, 1987
- Echocardiography reveals a high incidence of bicuspid aortic valve in Turner syndromeThe Journal of Pediatrics, 1983
- Organ-specific autoantibodies in children with common endocrine diseasesThe Journal of Pediatrics, 1982
- Thyroid abnormalities in 20 children with Turner syndromeThe Journal of Pediatrics, 1977
- Hypertension and aorticrupture in gonadal dysgenesisThe Journal of Pediatrics, 1971